Revealed: CSL’s secret plan to cut pay, sack workers
Australia’s third biggest company devised a plan to shift workers on to lower pay and conditions and make them redundant if they refused to relocate.
Australia’s third biggest company devised a plan to shift workers on to lower pay and conditions and make them redundant if they refused to relocate.
The weight loss drug is causing market value losses at healthcare leaders such as CSL and ResMed – but when will the market pay attention to the limits of what Ozempic may offer?
Protest vote lodged against winemaker’s remuneration. Qantas down as oil prices jump, loyalty boss quits. Fletcher plunges on Iplex claims. Liontown hit with downgrades as Albemarle walks away.
CSL’s falling share price on the back of the success of competitor Novo’s wonder-drug Ozempic is raising uncomfortable questions over its $18.2bn purchase of Vifor.
Court finds ANZ failed to inform market over 2015 placement. China’s flat inflation signals need for stimulus. Fletcher Building dismisses BGC’s plumbing claims. Perpetual lifts. Pact rejects billionaire investor’s bid.
CSL sinks past Covid lows. PwC former boss Luke Sayers tells Senate inquiry he feels terrible, but there were a ‘number of bad actor tax partners’. Tabcorp tanks. CBA tips ‘live’ RBA meeting. Redbubble soars.
The third-largest company on the ASX narrowly avoided a first strike as investors took the biotechnology player to task on plans to award performance rights to the CEO.
Gina Rinehart’s Hancock Prospecting has 19.9 per cent of Liontown. CSL avoids first strike. Profit fall, outlook weighs on BoQ. Qantas gains on chair exit.
Amid what seems like share market doom and gloom, brokers have a bright outlook on stocks across various sectors, including one with a 33 per cent upside.
Low oil price hits Woodside, Santos. Lithium miners fall on JP Morgan downgrade. Union bid to expand IR laws. Trade surplus up more than expected. AUD gains.
RBA holds rates at 4.1pc for fourth month. Inflation still too high: Bullock. US sale lifts Computershare. Avita tanks on new FDA hurdle. US, Aus bond yields hit new highs. Endeavour allows Wavish vote.
Australia’s biggest health company has revealed its flu shot is 15pc more effective than conventional ones. But don’t expect the government to pay for it.
Most people would groan at the thought of a future pandemic, but governments are determined not be caught out again, with the UK striking a new deal with CSL.
Qantas objected to Qatar flights but not decision maker: Hudson. Virgin boss says government stance on Qatar flights shifted. ASX down as CSL, Star fall. RBA rate hold tipped post inflation data.
Australia’s biggest health company is trialling a potentially groundbreaking treatment for one of the world’s most common respiratory conditions.
Australia’s vaccine powerhouse, CSL, is being accused of shifting $5bn to Switzerland to crush its tax bill at a time the company was tied up in giant government contracts.
The blood products and vaccine giant has opened a new $2bn headquarters in Melbourne, which will also house an incubator for 40 biotech start-ups.
It turns out one of the toughest decisions CSL chief Paul Makenzie had to make just weeks into his tenure was picking which AFL team to support.
Australia’s biggest health company says it has a suite of solutions to restore profit margins to pre-pandemic levels.
CSL, Pro Medicus, Cochlear lead health sector rally. AUD at US65c after lower quarterly wages growth. China reveals more economic weakness. NAB spikes on buyback. Seek tumbles.
Original URL: https://www.theaustralian.com.au/topics/csl/page/3